Navigation Links
Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty
Date:6/14/2013

ments include (but are not limited to) statements about expected benefits and risks associated with the Further Increased Offer; projections or expectations of profit attributable to shareholders; anticipated provisions or write-downs, economic profit, dividends, capital structure or any other financial items or ratios; statements of plans, objectives or goals of Elan, the Elan Group, RP Management or Royalty Pharma following the Further Increased Offer; statements about the future trends in interest rates, liquidity, foreign exchange rates, stock market levels and demographic trends and any impact that those matters may have on Elan, the Elan Group, RP Management or Royalty Pharma following the Further Increased Offer; statements concerning any future Irish, US or other economic environment or performance; statements about strategic goals, competition, regulation, regulatory approvals, dispositions and consolidation or technological or regulatory developments; and statements of assumptions underlying such statements.

Forward looking statements only speak as of the date on which they are made, and the events discussed in this announcement may not occur. Subject to compliance with applicable law and regulation, Royalty Pharma is not under any obligation to update publicly or revise forward looking statements, whether as a result of new information, future events or otherwise.

Rule 8 - Dealing Disclosure Requirements

Under the provisions of Rule 8.3 of the Irish Takeover Rules, if any person is, or becomes, "interested" (directly or indirectly) in 1% or more of any class of "relevant securities" of Elan, all "dealings" in any "relevant securities" of Elan (including by means of an option in respect of, or a derivative referenced to, any such "relevant securities") must be publicly disclosed by not later than 3.30 pm (Irish time) on the "business day" following the date of the relevant transaction. This requirement will continue until the date on w
'/>"/>

SOURCE Royalty Pharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Royalty Pharma Increases Offer to Acquire Elan to $13.00 Per Share in Cash Plus a Contingent Value Right of Up to $2.50 Per Share
2. Royalty Pharma Statement Regarding Elan Law Suits
3. Cadwalader Advises Elan Corporation in Billion Dollar Royalty Deal
4. Royalty Pharma Statement Regarding Elan Proposal
5. PDL BioPharma Provides Third Quarter 2012 Royalty Revenue Guidance of $85 Million
6. Cowen Healthcare Royalty Partners Raises $1 Billion
7. Smart Consulting Group and The Catalyst Group Form Alliance to Supply Quality Compliance Consulting Services For the Pharmaceutical Industry
8. Pursuit's Elissa Guerra and Eunjoo Pluenneke to Present on Mobile Strategy at Digital Pharma West Conference
9. MEI Pharma Adds Former YM BioSciences CEO Nick Glover To Board Of Directors
10. Frost & Sullivan Recognizes Sciformixs Continued Growth in the Increasingly Complex Pharmaceutical KPO Market
11. Auxilium Pharmaceuticals, Inc. To Present At The Goldman Sachs 34th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Scientists at NYU Langone Medical Center have found ... the process for turning adult cells into so-called pluripotent ... C. Using the new technique in mice, the researchers ... skin cells by more than 20-fold compared with the ... reliable, and thus should generally accelerate research aimed at ...
(Date:9/19/2014)... 19, 2014  Nektar Therapeutics (NASDAQ: ... characterizing the analgesic profiles of a series of ... agonist molecules. The preclinical research candidates were created ... The analgesic properties of kappa receptor ... 1,2 Kappa opioid receptors are expressed in ...
(Date:9/19/2014)... 19, 2014 ... ) has announced the addition of the  "Micro ... to their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... of the fastest-growing segments in the chromatography market. ... 2013, and expected to reach $2.0 billion by ...
(Date:9/18/2014)... About POCT POCT, ... clinical laboratory. It helps in making fast clinical ... medication. POCT is gaining popularity due to the ... as diabetes, heart disease, and obesity. It is ... to minimize errors during the diagnosis of patients. ...
Breaking Biology Technology:NYU Langone scientists report reliable and highly efficient method for making stem cells 2NYU Langone scientists report reliable and highly efficient method for making stem cells 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Micro Market Monitor : Global Pre-packed Chromatography Columns 2POCT Market in China 2014-2018 2
... (NPWH) Encourages Women to Get Informed and Ask ... growing awareness of HPV,(human papillomavirus), the primary cause of ... of Nurse Practitioners in Women,s,Health (NPWH) found that many ... prevent the disease. Despite the fact that there is ...
... Inc.,(Nasdaq: OSTE ), a leader in the emerging ... total revenue for the year,ending December 31, 2007 increased ... year ended December 31, 2006. Revenue from "core" product,lines, ... year,2007, an increase of 15% over core product revenue ...
... still flawed government-wide plan for nanotechnology risk research ... Federally-funded studies essential to managing possible risks from ... top-down strategy tied to projected commercialization, expected human ... , The National Nanotechnology Initiatives (NNI) ...
Cached Biology Technology:Survey Shows Most Women Can't Separate Fact From Fiction When It Comes to Cervical Cancer Prevention 2Survey Shows Most Women Can't Separate Fact From Fiction When It Comes to Cervical Cancer Prevention 3Survey Shows Most Women Can't Separate Fact From Fiction When It Comes to Cervical Cancer Prevention 4Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 2Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 3Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 4Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 5Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 6Federal nanotech risk research plan still comes up short 2
(Date:9/18/2014)... found clownfish larvae can swim up to 400 kilometres in ... cope with environmental change. , Clownfish spend their entire adult ... babies they must wander the open ocean, says study co-author, ... Coral Reef Studies (Coral CoE) at James Cook University. , ... now we,ve been given a rare glimpse into how far ...
(Date:9/17/2014)... UCLA atmospheric scientists were instrumental in the creation of ... tool to classify the fire threat potential of the ... a spark into an inferno. The index was introduced ... with UCLA and San Diego Gas and Electric. , ... to "extreme" that will be used to help fire ...
(Date:9/17/2014)... EC-FP5 four-year project, delivering its first release in 2004. ... in several EC projects, as a part of the ... BON), to increase the general awareness of the work ... dissemination of the Fauna Europaea results, the ... e-Publishing tools to prepare data papers for all 56 ...
Breaking Biology News(10 mins):Nemo's epic journey to find a new home 2UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2
... Leader, in One-Time Passwords for Highest Ability to Execute and ... RSA, The Security Division of EMC (NYSE: EMC ... An Overview and Competitive Analysis for the One Time ... in one-time password (OTP) technology for strong authentication based upon ...
... LA JOLLA, CA, June 19, 2009Researchers at The ... and Ohio State University have used a very sensitive ... to exist in one "natural" three-dimensional structure (shape), can ... the protein,s chemical environment. One folded form is active ...
... of nanomaterials with enhanced performance characteristics for use in ... people coming into direct contact with these materials. ... the market including clothes, skin lotions and cleaning ... and therapeutic nanocarriers have been designed for targeted drug ...
Cached Biology News:RSA Designated as the Leader in One-Time Password Market by Frost & Sullivan 2RSA Designated as the Leader in One-Time Password Market by Frost & Sullivan 3RSA Designated as the Leader in One-Time Password Market by Frost & Sullivan 4Researchers observe single protein dimers wavering between two symmetrically opposed structures 2Researchers observe single protein dimers wavering between two symmetrically opposed structures 3Researchers observe single protein dimers wavering between two symmetrically opposed structures 4Research explores interactions between nanomaterials, biological systems 2Research explores interactions between nanomaterials, biological systems 3Research explores interactions between nanomaterials, biological systems 4
... functional protein microarray is the first microarray ... interactions on a proteome scale. The Yeast ... frames (ORFs) expressed as 5'-GST fusions, purified ... inch x 3 inch nitrocellulose-coated slide. With ...
... Useful for the mechanical harvesting of cells ... ensures even contact with the growth surface ... 75cm flasks • Individually wrapped • Sterilized ... This CLS number is a new product ...
... description: Designed for use with dishes and ... is a new product number, created to ... no availability yet, please order under the ... service for assistance. Comp Dim: blade L ...
... combine the proven features of the pET, ... provides all of the benefits and versatility ... backbone. The pTriEx vectors have been extensively ... in all three expression systems. In each ...
Biology Products: